cross-posted from: https://mander.xyz/post/11304633

Ozempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5

  • @[email protected]
    link
    fedilink
    English
    139 months ago

    Ever since Ozempic became more profitable to sell to fat people looking for an easy weight loss hack rather than the diabetics who actually needed it, we’ve seen nothing but bullshit attributed to the drug.

    • @[email protected]
      link
      fedilink
      English
      119 months ago

      No medicines have copyrights, but they do have patents. And, drug patents are kinda necessary if you want money to be spent on developing new drugs.

      No one is going to dump a few hundred million into developing a new drug if everyone can manufacture and sell it upon release.

      Patents aren’t the issue, though, it’s companies charging out the ass because they can.

      • Sneezycat
        link
        fedilink
        English
        139 months ago

        Publicly funded research is out of the question then? Why does it have to be private corporations doing the research?

        • @[email protected]
          link
          fedilink
          English
          29 months ago

          A state doesn’t have this kind of money to burn. If they did it, the money would have to come from somewhere. So either you increase taxes, decrease spending elsewhere, or start a business making a lot of money. Such as, say, selling the newly developed medications at a markup… It’s sad, but I’m not aware of a better way.

          That being said, the cost of medications in the US is utterly ridiculous.

      • Io Sapsai 🌱
        link
        fedilink
        English
        49 months ago

        Oh, the patent expired? No problem, we’ll just methylate the structure, see that it makes no difference and put it out on the market as a new drug. Or maybe take the active part of a racemic mixture and half the dosage. Same drug double the patent. Semisynthetic insulin is even worse in that regard.

      • @[email protected]
        link
        fedilink
        English
        29 months ago

        No one is going to dump a few hundred million into developing a new drug if everyone can manufacture and sell it upon release.

        You won’t sell it on the market because you have to produce it cheaper or at the same cost as the competition. You don’t have the knowledge to produce the drug efficiently, and you can’t learn that by looking at the end product. In a society without IP, the most important things are the optimised production processes, which will be kept secret. The rest can be copied because it will be more expensive to produce.

  • @[email protected]
    link
    fedilink
    English
    29 months ago

    I read the article and I don’t think it factors in the upfront cost of R&D, Compliance, etc, so that’s basically a fantasy number.

    • @[email protected]
      link
      fedilink
      English
      3
      edit-2
      9 months ago

      You’re probably right. It’s more than likely the cost per dose. Which is also what the $1000 figure represents.

      The Vermont independent (Bernie) called on Novo Nordisk to lower the list price of Ozempic to $155 a month or less, in line with what it charges in other countries.

      Somehow they can justify selling it for $155 a dose (per month?) in other countries while still making a profit above the overhead and compliance costs.

    • @[email protected]
      link
      fedilink
      English
      39 months ago

      Those are the costs of doing business, and can be greatly exaggerated. And other counties produce profitable drugs even with price restrictions. We’re so accustomed to price gouging, that we don’t recognize it.